Fig. 4: Treatment with atovaquone and aPD-L1 does not cause toxicity. | Cell Death & Disease

Fig. 4: Treatment with atovaquone and aPD-L1 does not cause toxicity.

From: Antitumour effect of the mitochondrial complex III inhibitor Atovaquone in combination with anti-PD-L1 therapy in mouse cancer models

Fig. 4

BALB/c mice bearing subcutaneous CT26 tumours treated with ATO (200 mg/kg/day for 15 days by gavage) and/or anti-PD-L1 (a total of 5 × 10 mg/kg i.p. injections, administered every 3 days) starting at a tumour size of about 25 mm3. Mouse weight was recorded throughout the experiment (A). One day after the end of the treatment, blood was sampled by cardiac puncture under terminal anaesthesia, and haematological (B–D) and plasma clinical chemistry (E–I) parameters were measured. Mean values ± standard errors are shown. WBC White blood cells, ALT alanine aminotransferase. No statistically significant differences were found (ANOVA).

Back to article page